Combination CVD Meds Tied to Slower Cognitive Decline
'In individuals simultaneously using two or three medication classes, the decline of cognition was slower, equivalent to the change in cognition of a person 3 years younger than the average age on this sample,' Roshni Biswas, MBBS, PhD, MPH, research scientist, Rush Alzheimer's Disease Center, Chicago, told Medscape Medical News .
'Our findings suggest that early interventions with combination therapies targeting multiple vascular metabolic risk factors could potentially delay or prevent cognitive decline and dementia,' Biswas said.
The study was presented on July 27 at Alzheimer's Association International Conference (AAIC) 2025.
Heart-Brain Connections
Hypertension, dyslipidemia, and diabetes are known risk factors for dementia. Antihypertensives, lipid-lowering, and antidiabetic medications may help reduce the risk for dementia.
However, a few studies have examined the association of combination cardiovascular therapies with cognitive decline and dementia-related postmortem neuropathologies.
To that end, Biswas and colleagues evaluated 4651 older adults without dementia at baseline who participated in five ongoing longitudinal studies of aging and dementia at the Rush Alzheimer's Disease Center.
Participants underwent at least two annual cognitive assessments for an average of 9 years. Use of antihypertensive, lipid-lowering, and antidiabetic medications was documented annually.
In a subgroup of 1896 participants who had died and undergone autopsy, the researchers evaluated the extent of Alzheimer's disease (AD) and other dementia-related neuropathologies.
Synergistic Effects?
Compared with no medication use, treatment with all three medication classes was associated with a slower decline in global cognition ( P = .02), particularly semantic and working memory, the researchers found.
Among autopsied participants, treatment with all three medication classes was associated with lower odds of atherosclerosis (odds ratio [OR], 0.47; P < .01) and arteriolosclerosis (OR, 0.53; P = .01); less global AD pathology ( P < .01), specifically amyloid and tangles; and lower odds of hippocampal sclerosis (OR, 0.27; P = .03) and TDP-43 (OR, 0.46; P < .01), a protein increasingly recognized as a key player in AD pathology, particularly in its later stages.
Even treatment with just two medication classes was associated with a slower decline in global cognition ( P < .01), as well as lower odds of atherosclerosis (OR, 0.63; P < .01), less global AD pathology ( P = .03) and tangles ( P = .03), and lower odds of TDP-43 (OR, 0.71; P = .02).
Use of a single class of medication was associated with more limited but still measurable benefits, especially in preserving semantic memory and reducing tangles.
'Our study raises the possibility for increased beneficial effects of combination vascular metabolic therapies (as opposed to single therapy) in preventing cognitive decline and dementia in aging. However, further study is needed before making clinical recommendations,' Biswas told Medscape Medical News .
Reached for comment, Courtney Kloske, PhD, director of scientific engagement at the Alzheimer's Association, said this study supports the 'heart-brain connection' and demonstrates that 'controlling modifiable vascular risk factors could have beneficial impacts on the brain.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference
STOCKHOLM, SE / / August 5, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that an abstract about the preclinical project TrkA-NAM ACD137 against osteoarthritis and other severe pain conditions has been accepted for presentation at the international pain conference NeuPSIG 2025, to be held in Berlin, Germany, September 4-6. The abstract, titled Analgesic and anti-inflammatory effects of ACD137, a potent and selective negative allosteric modulator of TrkA , will be presented at NeuPSIG 2025 by Märta Segerdal, Head of Development and Chief Medical Officer at AlzeCure Pharma. Co-authors are Pontus Forsell, Maria Backlund, Veronica Lidell, Azita Rasti, Cristina Parrado-Fernandez, Johan Sandin and Gunnar Nordvall. The results show that the lead drug candidate in the project, ACD137, has potent analgesic effects in several different preclinical pain models. The analgesic effect of ACD137 in the study was as potent as the effect of the anti-NGF antibody Tanezumab, which has demonstrated significant and robust pain relief in several clinical trials. ACD137 achieves its effect by blocking NGF-mediated signaling via TrkA receptors, a biological mechanism with strong genetic, preclinical and clinical validation for its role in pain. These positive preclinical data in models of osteoarthritis, neuropathic pain and nociceptive pain further strengthen previous positive analgesic results obtained with ACD137 and further underline its broad applicability in various severe pain conditions, including osteoarthritis. "These data demonstrate that our drug candidate ACD137 is a highly potent and selective TrkA-NAM that exhibits significant analgesic effects in relevant preclinical animal models. Furthermore, this small molecule TrkA-NAM has the potential to avoid some of the side effects observed with anti-NGF antibodies due to a more selective mechanism of action, while maintaining analgesic efficacy," said Pontus Forsell, project leader and Head of Discovery and Research at AlzeCure Pharma. "The project is based on a mechanism with strong validation, both preclinically and clinically. The results we have for TrkA-NAM in pain are promising, and the fact that we also have anti-inflammatory effects with our substance opens up for broader application. The fact that this is also a mechanism that is not linked to the side effects and addiction problems observed with opioids and antibodies is of course also important for a potential future approval," said Martin Jönsson, CEO of AlzeCure Pharma AB. The abstract and the poster will be available on AlzeCure's website after the presentation ( For more information, please contact Martin Jönsson, CEOTel: +46 707 86 94 About AlzeCure Pharma AB (publ) AlzeCure ® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore ® , Alzstatin ® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease and is being prepared for phase 2. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain with positive phase 2 results, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit About TrkA-NAMThe TrkA-NAM project, which is in research phase, is focused on the treatment of pain. The target mechanism, NGF / TrkA signaling, is well-validated both preclinically and clinically and provides a promising alternative to new analgesics without the side effects and addiction problems observed with opioids. Substances developed in the project have recently been shown to also have anti-inflammatory properties. For the TrkA-NAM drug project, we have leveraged our knowledge concerning the underlying biology for the NeuroRestore platform in order to develop new compounds that focus on providing pain relief in conditions associated with severe pain. The goal of the project is to develop a small-molecule TrkA-negative allosteric modulator for the treatment of osteoarthritis pain and other severe pain disorders. The global osteoarthritis market is expected to reach USD 11.0 billion by 2025, from USD 7.3 billion in 2020. Growth in this market is driven by factors such as the increasing occurrence of osteoarthritis, the growing aging population, and an increase in the number of sports injuries. Over 400 million people worldwide suffer from painful and activity-limiting osteoarthritis of the hip or knee. Many patients experience insufficient pain relief or side effects with current treatment, which today usually consist of NSAIDs or opiates and there is a great need for more effective and better tolerated drugs in this field. Read more about TrkA-NAM on our homepage. Image Attachments Martin Jönsson CEO And Pontus Forsell Head Of D&R AlzeCure Pharma Attachments New scientific data with TrkA-NAM ACD137 against knee osteoarthritis to be presented at pain conference SOURCE: AlzeCure Pharma View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 hours ago
- Yahoo
Alzheimer's researchers say targeting brain sugar could help protect against dementia
The brain has a hidden "sugar code" that could lead to better treatments for neurological diseases like Alzheimer's, according to new research. A study recently published in the journal Nature Metabolism found that breaking down glycogen (stored glucose) in the brain could reduce the buildup of toxic proteins linked to the common dementia. This was one of the first studies to show that glycogen may actively influence brain health and disease, according to lead author Dr. Pankaj Kapahi, a professor at the Buck Institute for Research on Aging in California. Two Cancer Drugs Show Promise In Reversing Alzheimer's Devastating Effects "The study began with fruit flies (Drosophila) that were genetically modified to mimic tauopathy, a condition where a protein called tau builds up in the brain, similar to what happens in Alzheimer's disease," Kapahi told Fox News Digital. The flies used in the study were found to have brain damage and shortened lifespans, according to the researcher. Read On The Fox News App To ensure that the results could translate to humans, the research team also studied nerve cells made in the lab from human patient cells carrying tau mutations, as well as postmortem brain samples from people who had Alzheimer's or related conditions, according to a press release. In both the fly and human models, the researchers found increased levels of glycogen (stored glucose) in the brain, as well as signs that glycogen breakdown was impaired, Kapahi told Fox News Digital. This was a surprising discovery, as researchers previously thought glycogen was mainly stored in the muscles and liver. Alzheimer's Risk Could Rise With Specific Sleep Pattern, Experts Warn They also found that the excess glycogen contributed to disease. The tau proteins in the scientists' models interacted with glycogen, blocking it from breaking down, and the nerves lost their ability to ward off cell damage. However, the researchers found they could decrease damage to the fruit flies and human nerves by boosting an enzyme called glycogen phosphorylase (GlyP), which breaks down glycogen. The nerve cells used the glycogen to fight against cell damage, suggesting that the enzymes responsible for breaking down sugar could be promising targets for future therapies. The researchers were also curious whether a restricted diet could improve the flies' brain health. When they reduced the amount of protein in the insects' diet, the flies indeed lived longer and their brain health improved. "We then discovered this improvement was linked to an increase in the breakdown of glycogen," Kapahi said. This led to the study's main finding — that breaking down glycogen in neurons can protect the brain from damage caused by tau buildup. Eating These Common Foods Could Reduce Alzheimer's Risk, Experts Say The scientists also developed a drug using a special molecule called 8-Br-cAMP that replicated similar effects of dietary restriction, the press release noted. The authors clarified that they are not recommending low-protein diets just yet — but said this research could pave the way for dietary or drug-based strategies to help slow Alzheimer's and related diseases. Dr. Michael Okun, a Florida neurologist and medical advisor to the Parkinson's Foundation, was not involved in the study but commented on the significance of the findings. "Instead of funneling sugar into energy-burning processes, the broken-down glycogen seemed to be routed into an antioxidant-producing pathway," Okun, who is also author of "The Parkinson's Plan," told Fox News Digital. "The next step in the process may be mopping up potentially damaging free radicals roaming our brains," he said. Okun also confirmed that dietary restrictions activated a protective brain pathway and boosted the breakdown of brain sugar. "It ultimately reduced damage from the Alzheimer's-related tau protein," he said. The study — which was supported by the National Institutes of Health, as well as the American Federation of Aging Research and other sources — did have some limitations, the experts acknowledged. Click Here To Sign Up For Our Health Newsletter The researchers did not clarify whether breaking down brain glycogen could stop human brain cells from dying, Okun noted. "We don't yet know why glycogen builds up in disease, or whether it's a cause or a result of tau pathology — though our data suggest it may amplify disease progression," Kapahi added. The research was also conducted only on fly and human cell models and has not yet been tested on living humans. "We still don't know if targeting glycogen breakdown will work in human patients — and most importantly, whether it will be a safe approach," Okun said. Alzheimer's disease, the most common form of dementia in the U.S., affects more than seven million people in the U.S., according to the Alzheimer's Association. For more Health articles, visit The neurological disorder affects memory, thinking and behavior. There is no cure for the disease, but some medications can temporarily slow progression and improve quality of article source: Alzheimer's researchers say targeting brain sugar could help protect against dementia Solve the daily Crossword
Associated Press
a day ago
- Associated Press
Biomed Industries Presents Four Breakthrough Studies on Alzheimer's, Rett Syndrome, and Obesity Therapies at AAIC 2025
Biomed Industries, Inc. Presents Four Pivotal Studies at AAIC 2025 Highlighting Breakthrough Therapies for Alzheimer's, Rett Syndrome, and Obesity 'NA-831 is the only drug to date that has halted Alzheimer's disease progression. Combining it with existing drugs like Donanemab could optimize therapeutic efficacy and reduce serious side effects.'— Dr. Lloyd L. Tran, CEO of Biomed SAN JOSE, CA, UNITED STATES, August 4, 2025 / / -- Biomed Industries, Inc., a leading biopharmaceutical innovator developing transformative therapies for neurological and metabolic diseases, today announced the presentation of four major scientific papers at the Alzheimer's Association International Conference (AAIC), held July 27–31, 2025, in Toronto, Canada. The presentations featured Biomed's next-generation oral therapies for Alzheimer's disease, Rett syndrome, and obesity, with a focus on novel combination strategies designed to enhance safety, efficacy, and accessibility. Featured AAIC 2025 Presentations: 1. The End of the Amyloid Era? Evidence for a Paradigm Shift in the Quest to Treat Alzheimer's Disease 2. A Phase 3 Clinical Protocol of NA-831 Combined with Donanemab in Early Alzheimer's Disease: A Placebo-Controlled, Double-Blind Study 3. Associations Between Alzheimer's Disease and Rett Syndrome: Clinical Trials of NA-831 and NA-921 4. Neuro-Metabolic Link Between Alzheimer's Disease and Obesity: Clinical Evaluation of NA-831 and NA-931 1. PRESENTATION: The End of the Amyloid Era? A Paradigm Shift in Alzheimer's Research For over three decades, the 'amyloid hypothesis' has dominated Alzheimer's disease (AD) research, asserting that amyloid-β accumulation is a primary driver of neurodegeneration. Biomed's comprehensive analysis of Phase 3 trial data from seven anti-amyloid drugs — including aducanumab, lecanemab, donanemab, gantenerumab, bapineuzumab, crenezumab, and solanezumab — challenges this paradigm. Across all trials, both treatment and placebo groups exhibited similar cognitive decline, as measured by CDR-SB and ADAS-Cog. The average differences between treatment and placebo arms were minor and not clinically significant (CDR-SB: -0.25; ADAS-Cog: -0.79). Slope comparisons further revealed near-identical rates of decline between groups. 'Our analysis of Phase 3 clinical trial data for seven anti-amyloid drugs, including FDA-approved Aducanumab, Lecanemab, and Donanemab, indicates that none could halt disease progression in a clinically meaningful way — and all carried serious safety concerns,' said Dr. Zung Tran, VP of Biostatistics and AI at Biomed. 2. PRESENTATION: Phase 3 Clinical Protocol of NA-831 Combined with Donanemab NA-831, Biomed's lead oral candidate, is a first-in-class therapy that promotes neuroprotection, neurogenesis, and memory enhancement. Phase 2 trials demonstrated its disease-modifying potential with a favorable safety profile compared to traditional anti-amyloid drugs. In this upcoming Phase 3 study, NA-831 will be evaluated in combination with Donanemab, a recently FDA-approved monoclonal antibody, to explore synergistic effects. The goal is to lower Donanemab dosing, thereby reducing risks such as cerebral edema and microbleeds, while enhancing cognitive outcomes. 'NA-831 is the only drug to date that has halted disease progression in Phase 2 trials,' said Dr. Lloyd Tran, CEO of Biomed Industries. 'Combining it with existing drugs like Donanemab could optimize therapeutic efficacy and reduce serious side effects.' 3. PRESENTATION: Alzheimer's and Rett Syndrome: Shared Mechanisms and Dual Therapeutic Potential Biomed also presented findings on NA-921, a structural analog of NA-831 developed for Rett syndrome, a rare X-linked neurodevelopmental disorder. NA-921 modulates MeCP2 expression, targeting the disorder's core epigenetic dysfunction. A double-blind, placebo-controlled Phase 2/3 trial ( ID: NCT06849973) demonstrated promising results: Clinical Global Impression–Improvement (CGI-I) at week 12: NA-921: 3.60 | Placebo: 3.83 | P = 0.0020 | Effect size = 0.42 NA-921 was well tolerated, with a significantly improved safety profile compared to trofinetide: - Diarrhea: Trofinetide 82%, NA-921 24%, Placebo 19% - Vomiting: Trofinetide 29%, NA-921 9%, Placebo 11% - Fever: Trofinetide 9%, NA-921 5%, Placebo 4% These findings underscore a possible biological link between Alzheimer's disease and Rett syndrome, opening new cross-indication opportunities for NA-831 and NA-921. 4. PRESENTATION: Neuro-Metabolic Connections: NA-831 and NA-931 in Alzheimer's and Obesity Biomed's data also revealed compelling evidence of a neuro-metabolic bridge between Alzheimer's disease, diabetes, and obesity. In addition to NA-831's CNS benefits, Biomed is advancing NA-931, an oral quadruple receptor agonist (IGF-1, GLP-1, GIP, and glucagon) designed to treat obesity. In a 13-week Multiple Ascending Dose (MAD) study: - Mean body weight reduction: Up to 13.8% at 150 mg daily, 12.4% greater than placebo - ≥12% weight loss achieved by 72% of NA-931-treated patients vs. 2% in placebo group NA-931 demonstrated a strong safety profile, with mild and transient GI-related adverse events, and no observed muscle loss. 'Our pipeline shows how targeting interconnected pathways across the CNS and metabolic systems can unlock significant clinical potential,' said Michael Willis, VP of Business Development. 'With six active programs across Alzheimer's, ALS, Rett syndrome, stroke, obesity, and MASH, we are building a diversified platform to accelerate innovation and value creation.' ABOUT BIOMED INDUSTRIES, INC. Biomed Industries, Inc. is a pioneering biopharmaceutical company committed to developing novel therapeutics that address unmet medical needs. Its innovative research platform has produced treatments for conditions including Alzheimer's disease, ALS, Traumatic Brain Injury, Major Depressive Disorder, Diabetes, Obesity, MASH, Stroke, and rare diseases such as Huntington Disease and Rett Syndrome. (Website: ) Michael Willis Biomed Industries, Inc. email us here Visit us on social media: LinkedIn X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
